Table 1.
Impact on Low-Density Lipoprotein
| Study | n | Regimens | LDL- C Lowering (mg/dL) | Achieve LDL-C Goal (% of Patients) |
|---|---|---|---|---|
| EXPLORER14 | 469 | RSV/EZ 40 mg/10mg vs RSV 40 mg |
RSV/EZ: 70.0a RSV: 57.0 p<0.001 |
RSV/EZ: 94.0% RSV: 79.1% p<0.001 |
| Yang15 | 337 | RSV/EZ 5–20/10mg vs RSV 5–20mg | RSV/EZ: 59.5a RSV: 51.1 p<0.001 |
RSV/EZ: 90.7% RSV: 72.9% p=0.01 |
| MRS-ROZE16 | 407 | RSV/EZ 5–20/10mg vs RSV 5–20mg | RSV/EZ: 59.1b RSV: 49.4 p<0.001 |
RSV/EZ: 94.1% RSV: 86.3% p<0.05 |
| I-ROSETTE17 | 396 | RSV/EZ 5–20/10mg vs RSV 5–20mg | RSV/EZ: 75.4a RSV: 64.4 p<0.001 |
RSV/EZ: 92.3% RSV: 79.9% p<0.001 |
| Kim W18 | 712 | RSV/EZ 5–20/10mg vs RSV 5–20mg | RSV/EZ: 56.5%c RSV: 45.2% p<0.01 |
RSV/EZ: 94.2% RSV: 86.6% P=0.0142 |
| Hwang20 | 36 | RSV/EZ 5/10mg vs RSV 20mg | RSV/EZ: 94.3a RSV: 89.9 p=0.54 |
NR |
| Torimoto21 | 79 | RSV/EZ 2.5/10 mg vs RSV 5mg | RSV/EZ: 31.1%c RSV: 12.1% p<0.001 |
RSV/EZ: 89.7% RSV: 58.3% p=NR |
| Masuda22 | 51 | RSV/EZ 5/10mg vs RSV 5mg | RSV/EZ: 55.8%c RSV: 36.8% p=0.004 |
NR |
| Bays19 | 440 | RSV/EZ 5–10/10mg vs RSV 10–20 mg | RSV/EZ: 21.5%d RSV: 7.6% p<0.001 |
NR |
| Ambegaonkar25 | 8667 | Prior ST/EZ 10mg vs ST DD vs RSV 10mg vs SIM/EZ 20/10mg |
Prior ST/EZ: 26.0b ST DD: 9.7 RSV: 19.7 SIM/EZ: 27.6 |
NR |
| GRAVITY26 | 833 | RSV/EZ 10–20/10 mg SIM/EZ 40–80/10 mg |
RSV/EZ 10/10: 59.7a RSV/EZ 20/10: 63.5 SIM/EZ 40/10: 55.2 SIM/EZ 80/10: 57.4 p<0.001 |
RSV/EZ 10/10: 93.3 RSV/EZ 20/10: 95.6 SIM/EZ 40/10: 67.7 SIM/EZ 80/10: 88.6 p<0.007 |
Notes: aData represented as mean change in mg/dL. bData represented as least squares mean in mg/dL. cData represented as percent change from baseline. dData represented as percent change from baseline as a least squares mean.
Abbreviations: RSV, rosuvastatin; EZ, ezetimibe; SIM, simvastatin; LDL, low-density lipoprotein; ST, statin; DD, double-dose statin.